On August 19, Serenity evaluated the Yushu listing event, noting that its market value on the first day of trading was approximately $53.3 billion, making it the first significant public market benchmark in the field of humanoid robots. The next humanoid robotics company to watch is Agility Robotics, which has received support from NVIDIA and Amazon and is expected to go public in Q4 with a valuation of $2.5 billion. Serenity believes that pure humanoid robotics companies have garnered public market demand far exceeding expectations.
This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.




















Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.









